Medtronic PLC vs Health Care Select Sector SPDR Fund — how do they compare? Medtronic PLC trades at $90.65 (market cap $116.07B), while Health Care Select Sector SPDR Fund trades at $168.51. The key difference: Medtronic PLC pays a 3.18% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| MDT | XLV | |
|---|---|---|
Market Cap | $116.07B | — |
Sector | Health | — |
52-Week High | $105.35 | $168.44 |
52-Week Low | $73.75 | $131.16 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.93, down 0.3% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad healthcare exposure with a low expense ratio of 0.08% and a trailing dividend yield of 1.6%, positioning it as a cost-effective defensive play amid market volatility. Recent news highlights strong sector inflows and defensive demand, with earnings from key holdings like UnitedHealth showing resilience despite Medicaid pressures.
The outlook for XLV is positive, supported by its defensive characteristics and institutional interest, though risks include regulatory pressures and sector-specific volatility. Investors may find value in its diversification and steady performance, but should monitor healthcare policy developments and earnings trends for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →